ACADIA Pharmaceuticals (ACAD) Expected to Announce Quarterly Earnings on Wednesday

ACADIA Pharmaceuticals (NASDAQ:ACAD) is anticipated to announce its Q3 2025 results after the market closes on Wednesday, November 5th. Analysts expect the company to announce earnings of $0.14 per share and revenue of $276.5220 million for the quarter. Investors may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Wednesday, November 5, 2025 at 4:30 PM ET.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.02. ACADIA Pharmaceuticals had a return on equity of 14.69% and a net margin of 21.80%.The company had revenue of $264.57 million for the quarter, compared to analyst estimates of $263.07 million. During the same period in the prior year, the company posted $0.20 EPS. ACADIA Pharmaceuticals’s quarterly revenue was up 9.4% on a year-over-year basis. On average, analysts expect ACADIA Pharmaceuticals to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

ACADIA Pharmaceuticals Stock Down 1.5%

Shares of ACAD opened at $22.37 on Tuesday. The business’s 50 day moving average is $22.95 and its two-hundred day moving average is $21.78. ACADIA Pharmaceuticals has a 52-week low of $13.40 and a 52-week high of $26.65. The firm has a market cap of $3.77 billion, a price-to-earnings ratio of 16.82, a PEG ratio of 7.90 and a beta of 0.75.

Insiders Place Their Bets

In related news, Director Elizabeth A. Garofalo sold 1,600 shares of the company’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $25.98, for a total transaction of $41,568.00. Following the completion of the transaction, the director directly owned 25,382 shares in the company, valued at $659,424.36. This represents a 5.93% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Mark C. Schneyer sold 22,000 shares of the company’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $25.18, for a total value of $553,960.00. Following the transaction, the executive vice president owned 40,130 shares of the company’s stock, valued at approximately $1,010,473.40. The trade was a 35.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 27,098 shares of company stock valued at $678,256. 26.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Thrivent Financial for Lutherans grew its stake in shares of ACADIA Pharmaceuticals by 0.7% in the second quarter. Thrivent Financial for Lutherans now owns 91,067 shares of the biopharmaceutical company’s stock worth $1,964,000 after purchasing an additional 626 shares in the last quarter. Cetera Investment Advisers grew its stake in shares of ACADIA Pharmaceuticals by 7.9% in the second quarter. Cetera Investment Advisers now owns 12,763 shares of the biopharmaceutical company’s stock worth $275,000 after purchasing an additional 931 shares in the last quarter. Raymond James Financial Inc. grew its stake in shares of ACADIA Pharmaceuticals by 4.9% in the second quarter. Raymond James Financial Inc. now owns 29,679 shares of the biopharmaceutical company’s stock worth $640,000 after purchasing an additional 1,396 shares in the last quarter. California State Teachers Retirement System grew its stake in shares of ACADIA Pharmaceuticals by 1.4% in the second quarter. California State Teachers Retirement System now owns 100,691 shares of the biopharmaceutical company’s stock worth $2,172,000 after purchasing an additional 1,412 shares in the last quarter. Finally, AQR Capital Management LLC grew its stake in shares of ACADIA Pharmaceuticals by 3.8% in the first quarter. AQR Capital Management LLC now owns 67,672 shares of the biopharmaceutical company’s stock worth $1,124,000 after purchasing an additional 2,492 shares in the last quarter. 96.71% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ACAD has been the subject of a number of research analyst reports. Wall Street Zen downgraded ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, September 5th. Citigroup initiated coverage on ACADIA Pharmaceuticals in a report on Tuesday, October 21st. They issued a “buy” rating and a $33.00 price target for the company. TD Cowen boosted their price target on ACADIA Pharmaceuticals from $35.00 to $39.00 and gave the company a “buy” rating in a report on Thursday, September 11th. UBS Group boosted their price target on ACADIA Pharmaceuticals from $36.00 to $39.00 and gave the company a “buy” rating in a report on Tuesday, September 9th. Finally, Cowen reiterated a “buy” rating on shares of ACADIA Pharmaceuticals in a report on Thursday, September 11th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, ACADIA Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $29.33.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.